Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux

Launched by MUHAMMAD AAMIR LATIF · Mar 22, 2025

Keywords

ClinConnect Summary

Since the FDA issued a warning against domperidone as a potential proarrhythmic drug in children, its use has been widely discouraged and no longer recommended in safe practices. This warning at one end persuaded the pediatricians to search for the new options; on the other end, the use of metoclopramide, H2 receptor antagonists, and alginate-based medications became superfluous, opening a wide area of research in search of the next potential best option. The findings of this study would add to the existing statistics and help clinicians to have better outcomes among infants with gastroesop...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants of any gender
• • Aged 1-12 months
• • Presenting with symptoms of gastroesophageal reflux disease not responding to dietary modifications and positioning
• • Afebrile at the time of presentation
• • Vitally stable
• Exclusion Criteria:
• • No evidence of hypertrophic pyloric stenosis on ultrasonography
• • Children with congenital heart disease
• • Any history of prior illness associated with symptoms
• • With abdominal distension
• • Neurological impairment, like developmentally delayed, grossly microcephalic